摘要
背景:糖尿病肾病是糖尿病患者最重要的并发症之一。对于糖尿病肾病的发病机制至关重要的主要步骤包括通过AMP激活激酶(AMPK)和哺乳动物雷帕霉素(mTOR),活性氧产生和糖尿病或高血糖条件下的内质网应激调节细胞信号传导。这些过程介导肾细胞的增加的损失,例如足细胞,其相应地导致肾损伤和肾功能的丧失,例如糖尿病肾病中的结构完整性和肾小球滤过。抗糖尿病药二甲双胍广泛用于糖尿病患者的药物治疗。除了抗糖尿病作用外,最近的研究发现二甲双胍在体外和体内都有额外的肾保护作用。发现二甲双胍在不同的实验肾脏环境中减少凋亡。此外,显示出可以减少糖尿病大鼠以及2型糖尿病患者的白蛋白尿。证明这些作用是通过AMPK / mTOR信号轴介导的。这些数据表明二甲双胍对糖尿病肾病的有益和肾脏保护作用。目的:在本次综述中,我们将总结二甲双胍体外和体内肾保护作用的最新发现。此外,我们将描述和讨论这种药物治疗糖尿病肾病的治疗潜力。
关键词: 二甲双胍,高血糖,糖尿病肾病,肾脏,肾损伤,糖尿病,足细胞,AMP激活蛋白激酶。
Current Medicinal Chemistry
Title:Update on the Protective Renal Effects of Metformin in Diabetic Nephropathy
Volume: 24 Issue: 31
关键词: 二甲双胍,高血糖,糖尿病肾病,肾脏,肾损伤,糖尿病,足细胞,AMP激活蛋白激酶。
摘要: Background: Diabetic nephropathy is one of the most important complications in patients with diabetes mellitus. Main steps crucial for the pathogenesis of diabetic nephropathy involve amongst others the modulation of cell signaling via AMP-activated kinase (AMPK) and mammalian target of rapamycin (mTOR), reactive oxygen generation, and endoplasmic reticulum stress under diabetic or hyperglycemic conditions. These processes mediate increased loss of renal cells, such as podocytes, which consequentially leads to renal damage and loss of renal functions, such as structural integrity and glomerular filtration in diabetic nephropathy. The anti-diabetic drug metformin has been widely used for pharmacotherapeutic treatment of patients with diabetes mellitus. Besides its anti-diabetic actions, recent studies revealed additional nephroprotective effects of metformin in vitro and in vivo. Metformin was found to diminish apoptosis in different experimental renal settings. Moreover, it was shown to reduce albuminuria in diabetic rats as well as in patients with type 2 diabetes mellitus. These effects were demonstrated to be mediated via the AMPK/mTOR signaling axis. These data indicate beneficial and renoprotective effects of metformin in diabetic nephropathy.
Objective: In this review, we will summarize the latest findings regarding the nephroprotective impact of metformin in vitro and in vivo. Moreover, we will depict and discuss the therapeutic potential of this drug for the treatment of diabetic nephropathy.
Export Options
About this article
Cite this article as:
Update on the Protective Renal Effects of Metformin in Diabetic Nephropathy, Current Medicinal Chemistry 2017; 24 (31) . https://dx.doi.org/10.2174/0929867324666170404143102
DOI https://dx.doi.org/10.2174/0929867324666170404143102 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coronary Artery Disease in Patients with Chronic Kidney Disease: A Clinical Update
Current Cardiology Reviews Implication for Thiazolidinediones (TZDs) as Novel Potential Anti- Inflammatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design Application of MALDI/SELDI Mass Spectrometry to Cancer Biomarker Discovery and Validation
Current Proteomics The Anti-fibrotic Hormone Relaxin is not Reno-protective, Despite Being Active, in an Experimental Model of Type 1 Diabetes
Protein & Peptide Letters Hypertension and Cardiovascular Risk: The Importance of a Global Approach to Risk Management in the Light of Current Hypertension Guidelines
Current Hypertension Reviews microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design The Role of Diabetes in Molecular Pathogenesis of Cancer
Current Signal Transduction Therapy Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies
Current Vascular Pharmacology Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Renovascular Hypertension: Lesion Detection, Patient Selection, Treatment Options and Results
Current Hypertension Reviews T-type Ca Channel Blockers in Patients with Chronic Kidney Disease in Clinical Practice
Current Hypertension Reviews Growth Arrest Specific Gene (GAS) 6 Modulates Platelet Thrombus Formation and Vascular Wall Homeostasis and Represents an Attractive Drug Target
Current Pharmaceutical Design Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases
Current Clinical Pharmacology Olmesartan Reduces Pentosidine Production and Ameliorates Fragility of Bone in Ovariectomized Fructose-Fed Rats
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Bitter Gourd (Momordica charantia) is a Cornucopia of Health: A Review of its Credited Antidiabetic, Anti-HIV, and Antitumor Properties
Current Molecular Medicine Treatment of Atherosclerotic Renovascular Disease
Current Hypertension Reviews Toll-Like Receptors and their Role in Renal Pathologies
Inflammation & Allergy - Drug Targets (Discontinued) Editorial [Hot Topic:Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design